Premium
Dose response for travoprost ® in the glaucomatous beagle
Author(s) -
MacKay Edward O.,
McLaughlin Marsha,
Plummer Caryn E.,
BenShlomo Anna,
Gelatt Kirk N.
Publication year - 2012
Publication title -
veterinary ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.594
H-Index - 50
eISSN - 1463-5224
pISSN - 1463-5216
DOI - 10.1111/j.1463-5224.2011.00934.x
Subject(s) - travoprost , beagle , intraocular pressure , glaucoma , ophthalmology , medicine , pupil size , pupil , latanoprost , biology , neuroscience
Objective To evaluate the changes in intraocular pressure (IOP) and pupil size in 12 Beagles with inherited glaucoma after instillations of 0.033, 0.0033, 0.001, 0.00033, and 0.0001% travoprost (Travatan®‐Alcon Laboratories, Inc., Ft Worth, TX, USA) in multiple single‐dose studies. Procedures Intraocular pressure and pupil diameter (PD) measurements were obtained at 9 am , 12 pm , 3 pm , and 9 am the following day (24 h) in two groups of six glaucoma dogs. After 7 days, the vehicle or concentration was repeated in the contralateral eye of the same animals. Results Concentrations of 0.00033, 0.001, and 0.0033% travoprost significantly lowered IOP and PD, but the 0.0001% concentration provided limited IOP changes, although PD changes were still significant. This suggests travoprost is effective in the dog to lower IOP and reduce pupil size at concentrations starting between 0.0001 and 0.00033%. Conclusions The dose response for travoprost in the glaucomatous Beagle indicates this model is highly sensitive to this group of drugs, even at concentrations as low as 0.00033% (1/12 the commercially available concentration).